| Boehringer–Topas Therapeutics: immuno modulatory compounds, 201804– collab €na multi-y research + option agreem |
2018-04-24 |
| Freenome–Biognosys: proteomic technology, 201804– collab enhancing circulating NA cancer test with proteomics data |
2018-04-24 |
| Revolution Medicines–Nextech Invest: investment, 201804 financing round Series B totalling $56m incl lead investor Nextech Invest |
2018-04-24 |
| Revolution Medicines–SEVERAL: investment, 201804 financing round Series B $56m led by Nextech Invest |
2018-04-24 |
| Bosch–Randox: point-of-care diagnostics, –201804 collab developm test panels for Vivalytic POC analyser |
2018-04-21 |
| Merck (DE)–P&G: investment, 201804 acquisition €3.4b in cash of Merck’s consumer healthcare by P&G |
2018-04-19 |
| AiCuris–Max Planck: anti-infectives, 2018004– collab discovery of antibiotics + virostatic compounds extending existent collab with MPI-MP |
2018-04-18 |
| InterAx Biotech–LeadXPro: cancer immunotherapy, 201804– collab €na drug discovery + optimisation of lead molecules targeting GPCRs |
2018-04-18 |
| Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz |
2018-04-18 |
| Tizona Therapeutics–Minapharm: biopharma production, 201804– supply service cell line + process developm + production of therap antibody by ProBioGen |
2018-04-18 |
| Anasys Instruments–Bruker: investment, 201804 acquisition of Anasys by Bruker |
2018-04-17 |
| DiaMan–GlucoMe: digital health, 201804– collab product integration of GlucoMe + DiaMan products + marketing in Central America by DiaMan |
2018-04-17 |
| DKSH–Bruker: analytical instruments, 201804– distribution multi-product line of Bruker AXS in KR + AU + NZ + SG + ID by DKSH Technology |
2018-04-17 |
| Biovertis–Deinove: investment, 201804–201805 acquisition of Biovertis/Morphochem for €900k in 500k new shares + 8m warrants |
2018-04-13 |
| Enterprise Therapeutics–Novartis: investment, 201804 financing round Series B totalling £29m ($41m) incl co-lead investor Novartis Venture Fund |
2018-04-12 |
| Enterprise Therapeutics–SEVERAL: investment, 201804 financing round Series B £29m ($41m) co-led by Versant Ventures + NVF |
2018-04-12 |
| Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform |
2018-04-12 |
| Shire–Takeda: investment, 201804–201901 acquisition $62.2b (incl debt approx $80b) for $30.33 per share in cash + 0.839 Takeda shares per share |
2018-04-12 |
| Petra Pharma–Evotec: drug development services, 201804– supply service €na support developm of Petra-01 through to IND |
2018-04-11 |
| Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology |
2018-04-11 |
| Baliopharm–Promethera: investment, 201804 acquisition €na of Baliopharm AG by Promethera Biosciences SA |
2018-04-10 |
| Boehringer–Biomax: bioinformatics, 201804– license multi-year for BioXM s/w + license extension for BioRS s/w |
2018-04-10 |
| Promethera–MacDougall Biomedical Communications: public relations, 201804 service existent by MacDougall |
2018-04-10 |
| AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share |
2018-04-09 |
| Grünenthal–Univ Leuven: pain drugs, 201804– collab r+d non-opioid pain drugs with CD3 + LICR |
2018-04-09 |
| Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share |
2018-04-09 |
| Rebiotix–Ferring: investment, 201804 acquisition of Rebiotix by Ferring |
2018-04-05 |
| Arvinas–Nextech Invest: investment, 201804 financing round Series C totalling $55m incl new + lead investor Nextech Invest |
2018-04-04 |
| Arvinas–SEVERAL: investment, 201804 financing round Series C $55m led by Nextech Invest |
2018-04-04 |
| Boehringer–OSE Immunotherapeutics: antibody cancer drug, 201804– collab + license ww OSE-172 €30m upfront+short-term + €1.1b milestones + royalties |
2018-04-04 |
| Bravos Biosciences–Arsanis: therapeutic antibody, 201804– license pre-clin develop ww excl to ASN200 program + option further developm to BB100 LLC |
2018-04-04 |
| LCF Rothschild–Andera Partners: investment, 201804 management buy-out of EdRIP by employees + renaming to Andera Partners |
2018-04-04 |
| Brainomix–Boehringer: investment, 201804 financing round totalling £7m incl new + co-investor BIVF |
2018-04-03 |
| Brainomix–SEVERAL: investment, 201804 financing round £7m led by Parkwalk Advisors + incl BIVF + Chimera Partners + Oxford Univ |
2018-04-03 |
| Macrolide–Advent Venture Partners: investment, 201804 financing round totalling $20m incl existing investor Advent Life Sciences |
2018-04-01 |
| Macrolide–Bertarelli Group: investment, 201804 financing round totalling $20m incl existing investor Gurnet Point Capital |
2018-04-01 |
| Macrolide–GSK: investment, 201804 financing round totalling $20m incl existing investor SR One |
2018-04-01 |
| Macrolide–Novartis: investment, 201804 financing round totalling $20m incl existing investor Novartis Venture Fund |
2018-04-01 |
| Macrolide–Roche: investment, 201804 financing round totalling $20m incl existing investor Roche Ventures |
2018-04-01 |
| Macrolide–SEVERAL: investment, 201804 financing round $20m led by existing investors Advent LS + Gurnet Point + Novartis + Roche + SR One |
2018-04-01 |
| Abionic–SEVERAL: investment, 201808 financing round Series C CHF20m led by P Bottinelli + incl Investiere AG + ZKB + high net worth individuals |
2018-03-28 |
| Novartis–GSK: investment, 201803– acquisition $13b of 36.5% stake of Novartis in OTC joint venture giving GSK 100% ownership |
2018-03-27 |
| PITBUL project–EU (govt): grant, 201803–2020 Horizon 2020 grant €3.8m to develop ultrafast PoC tuberculosis diagnostic platform |
2018-03-24 |
| NMD Pharma–ABP (NL): investment, 201803 financing round Series A totalling €38m incl new + lead investor Inkef Capital |
2018-03-23 |
| NMD Pharma–Lundbeck: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Lundbeckfonden Emerge |
2018-03-23 |
| NMD Pharma–Novo Group: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Novo Seeds |
2018-03-23 |
| NMD Pharma–Roche: investment, 201803 financing round Series A totalling €38m incl new + co-investor Roche Venture Fund |
2018-03-23 |
| NMD Pharma–SEVERAL: investment, 201803 financing round Series A €38m led by new investor Inkef Capital + incl RVF + Novo Seeds + Lundbeckfonden |
2018-03-23 |
| MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market |
2018-03-22 |
| Aton–Grifols: investment, 201803– acquisition 100% of Haema for €220 on a debt free basis by Grifols from Aton GmbH |
2018-03-20 |
| Novartis–Harvard Univ: drug delivery technology, 201803– collab develop biomaterial systems for delivery of cancer immuntherapies NIBR + Wyss + Dana |
2018-03-20 |
| Robert Bosch Hospital–bio.logis: genetic software, 201803– supply implementation of bio.logis GIMS IT platform at RBK |
2018-03-20 |
| Bruker–KAUST: magnet resonance technology, 201803– collab establ KAUST-Bruker Center of Excellence in Magnetic Resonance |
2018-03-18 |
| KAUST–Bruker: magnetic resonance technology, 201803 supply 500 MHz super wide-bore MRI spectrometer at KAUST-Bruker CoE in Magnetic Resonance |
2018-03-18 |
| KAUST–Bruker: magnetic resonance technology, 201803 supply 900 MHz wide-bore NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance |
2018-03-18 |
| KAUST–Bruker: magnetic resonance technology, 201803 supply 950 MHz NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance |
2018-03-18 |
| KAUST–Bruker: magnetic resonance technology, 201803 supply DNP NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance |
2018-03-18 |
| Biocatalysts Ltd–BRAIN: investment, 201803 acquisition of majority stake in Biocatalysts Ltd by BRAIN AG |
2018-03-17 |
| Mérieux–Sartorius: bioreactors, 201803 supply of single-use viral vector manufacturing package to ABL Europe in Strasboug by SSB |
2018-03-16 |
| Prexton Therapeutics–Lundbeck: investment, 201803– acquisition €100m upfront + €805m developm + sales milestones ANNOUNCED |
2018-03-16 |
| Siemens–SEVERAL: investment, 201803 IPO €4.2b of Siemens Healthineers AG at FSE floating 150m (15% of) shares at €28/share |
2018-03-16 |
| Boehringer–Vanderbilt Univ: MCL1 inhibitors, 201803– collab expansion r+d of MCL1 inhibitors for cancer |
2018-03-13 |
| Danaher–KAUST: microscopy, 201803– collab establ KAUST-Leica Center of Excellence in Optical Microscopy |
2018-03-12 |
| ImmBioMed–Sekisui: coagulation tests, 201803 acquisiton of specialty coagulation assets of Sekisui Diagnostics GmbH by ImmBioMed |
2018-03-12 |
| KAUST–Danaher: microscopy, 201803 supply SP8 confocal platform to new KAUST-Leica Center of Excellence in Optical Microscopy |
2018-03-12 |
| Medical Univ Vienna–bio.logis: genetic software, 201803 collab use of bio.logis GIMS.DRM with safety code card at MUW |
2018-03-12 |
| Atomwise–SEVERAL: investment, 201803 financing round Series A $45m co-led by Monsanto GV + DCVC (Data Collective) + B Capital Group |
2018-03-07 |
| Compugen–JSR Corp: cell line development, 201803– license to use Selexis’ SUREtechnology for developm of cancer antibody drugs incl COM701 |
2018-03-07 |
| Novartis–Science 37: clinical research, 201803– collab 3y expansion up to 10 decentralised clinical trials |
2018-03-07 |
| Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size |
2018-03-07 |
| Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform |
2018-03-05 |
| abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals |
2018-03-01 |
| Affiris–PR&D: public relations, 201803 service existent by PR&D – Public Relations for Research & Education |
2018-03-01 |
| BioMedPartners–SEVERAL: investment, 201805 final closing CHF25m of BioMedInvest III fund bringing total to CHF100m |
2018-03-01 |
| Heidelberg Pharma–MC Services: public relations, 201803 service existent by MC Services |
2018-03-01 |
| Heidelberg Pharma–Univ Texas: personalised medicine, 201803– license for Dx + Tx of cancer patients w RNA polymerase II deletion |
2018-03-01 |
| R-Biopharm–Bosch: molecular diagnostics, 201803– collab €na developm tests for Vivalytic platform + sale of system with tests by R-Biopharm |
2018-03-01 |
| Berlin Cures–Russo Partners: public relations, 201802 service existent by Russo Partners |
2018-02-26 |
| Bruker–Evosep: liquid chromatography, –201802 collab product integration of timsTOF Pro MS + Evosep One LC for HT clinical proteomics |
2018-02-26 |
| Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies |
2018-02-26 |
| IRM² Infrarot Mikroskopie und Messtechnik GmbH–Bruker: investment, 201802 acquisition €na of IRM² by Bruker |
2018-02-22 |
| Aimmune Therapeutics–Nestlé: investment, 201802–201803 public offering totalling $202.4m incl $30m from existing investor Nestlé Health Science |
2018-02-20 |
| Aimmune Therapeutics–SEVERAL: investment, 201802–201803 public offering $176m+$26.4m net $190m with 5.5m+825k shares common stock at $32/share |
2018-02-20 |
| Cullinan Oncology–MAB Discovery: antibody cancer drug, 201802– collab developm of MAbs based on MAB Discovery’s discovery platform |
2018-02-20 |
| Gain Therapeutics–SEVERAL: investment, 201802 investment spin-off of Minorix’ SEE-Tx platform as Gain Therapeutics with Swiss investors + TiVenture |
2018-02-20 |
| ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer |
2018-02-15 |
| Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 |
2018-02-15 |
| Flatiron Health–Roche: investment, 201802–201804 acquisition $1.9b of remaining 87.4% not already owned by Roche |
2018-02-15 |
| Mologen–SEVERAL: investment, 201802–201803 capital increase €4.99m with 2.36m new shares at €2.12/share to existing + new investors |
2018-02-15 |
| Pieris–SEVERAL: investment, 201802 public offering $50.6m with 5.5m+825k common shares at $8/share |
2018-02-13 |
| Swiss Medical Imaging Investment–RAD-x: investment, 201802 acquisition of SMII by RAD-x |
2018-02-13 |
| Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share |
2018-02-12 |
| Lonza–Kirkstall: cell culture system, 201802– collab ww marketing + distribution of Quasi Vivo System by Lonza |
2018-02-12 |
| Pieris–Trophic Communications: public relations, 201802 service existent media relations by Trophic |
2018-02-09 |
| Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins |
2018-02-09 |
| Pfizer–Genedata: bioinformatics, 201802– supply license for Genedata Bioprocess enterprise platform to Pfizer Inc |
2018-02-08 |
| Thermo Fisher–Endress+Hauser: lab automation, 201802 collab product integration of AJ’s CyBio FeliX system in cell-free DNA extraction device |
2018-02-07 |
| Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases |
2018-02-06 |
| Faron Pharmaceuticals–Lyomark Pharma: Traumakine, 201802– supply contract manfucturing by Lyocontract GmbH |
2018-02-05 |
| Faron Pharmaceuticals–Rentschler: Traumakine, 201802 supply existent contract manfucturing by Rentschler Biopharma SE |
2018-02-05 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
1 2 3 ... 10 11 12 ... 53 54 55 
Date![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
